Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

Circulation

Volumn 129, Issue 5, 2014, Pages 587-597

  Cherney, David Z I ^a   Perkins, Bruce A ^b   Soleymanlou, Nima ^c   Maione, Maria ^a   Lai, Vesta ^a   Lee, Alana ^a   Fagan, Nora M ^d   Woerle, Hans J ^e   Johansen, Odd Erik ^e   Broedl, Uli C ^e   Von Eynatten, Maximilian ^d  

^a Division of Nephrology   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

diabetes mellitus; diabetic nephropathies; hypertension; nitric oxide; renal; renin angiotensin system; SGLT2 protein

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CREATININE; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; NITRIC OXIDE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F1 ALPHA; SODIUM GLUCOSE COTRANSPORTER 2; THROMBOXANE B2;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; BACKACHE; BODY MASS; CARBOHYDRATE INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DECREASED APPETITE; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DIZZINESS; DRUG WITHDRAWAL; DYSMENORRHEA; DYSURIA; EAR INFECTION; EYE INFECTION; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HEADACHE; HEMODYNAMICS; HEMORRHOID; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCREASED APPETITE; INFLUENZA; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; KIDNEY TUBULE NECROSIS; KIDNEY VASCULAR RESISTANCE; LUNG INFECTION; MALE; MALLORY WEISS SYNDROME; MEAN ARTERIAL PRESSURE; MENSTRUATION DISORDER; MYALGIA; NAUSEA; NOCTURIA; NOCTURNAL HYPOGLYCEMIA; OPEN STUDY; PLASMA RENIN ACTIVITY; POLLAKISURIA; POLYDIPSIA; PRIORITY JOURNAL; PROTEIN DIET; PRURITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; RHINOPHARYNGITIS; SHORT COURSE THERAPY; SINUS CONGESTION; SKIN IRRITATION; SMOKING; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; THROAT IRRITATION; TINNITUS; TOOTH INFECTION; ULTRAFILTRATION; URINARY EXCRETION; URINARY TRACT INFECTION; URINE VOLUME; VAGINA BLEEDING; VAGINAL DRYNESS; VAGINITIS; VERTIGO; VOMITING; XEROSTOMIA;

DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HYPERTENSION, RENAL; NITRIC OXIDE; RENIN-ANGIOTENSIN SYSTEM; SGLT2 PROTEIN;

ADULT; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 1; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSE CLAMP TECHNIQUE; GLUCOSIDES; HEMODYNAMICS; HUMANS; KIDNEY; MALE; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893214045     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.005081     Document Type: Article

References (50)

1. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med. 1982;72:375-380.
2. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int. 1981;19:410-415.
3. Brenner BM, Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA. The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy. Acta Endocrinol Suppl (Copenh). 1981;242:7-10.
4. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia. 2009;52:691-697.
5. Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Dodesini AR, Trevisan R, Bossi A, Zaletel J, Remuzzi G; GFR Study Investigators. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061-2068.
6. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010;53:2093-2104.
7. Sasson AN, Cherney DZ. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes. 2012;3:1-6.
8. Cherney DZ, Reich HN, Jiang S, Har R, Nasrallah R, Hébert RL, Lai V, Scholey JW, Sochett EB. Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol. 2012;303:R710-R718.
9. Cherney DZ, Konvalinka A, Zinman B, Diamandis EP, Soosaipillai A, Reich H, Lorraine J, Lai V, Scholey JW, Miller JA. Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care. 2009;32:91-93.
10. Cherney DZ, Miller JA, Scholey JW, Bradley TJ, Slorach C, Curtis JR, Dekker MG, Nasrallah R, Hébert RL, Sochett EB. The effect of cyclooxygenase- 2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes. 2008;57:688-695.
11. Sochett EB, Cherney DZ, Curtis JR, Dekker MG, Scholey JW, Miller JA. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol. 2006;17:1703-1709.
12. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999;10:2569-2576.
13. Malatiali S, Francis I, Barac-Nieto M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res. 2008;2008:305403.
14. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515-531.
15. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302:R75-R83.
16. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2:.
17. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes. 2012;5:313-327.
18. L ist JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-657.
19. Mudaliar S, Armstrong DA, Mavian AA, O'Connor-Semmes R, Mydlow PK, Ye J, Hussey EK, Nunez DJ, Henry RR, Dobbins RL. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012;35:2198-2200.
20. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, Saito A. Improved diabetic syndrome in C57BL/KsJ-db/ db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol. 2001;132:578-586.
21. Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther. 2013;345:464-472.
22. Cherney DZ, Miller JA, Scholey JW, Nasrallah R, Hébert RL, Dekker MG, Slorach C, Sochett EB, Bradley TJ. Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes. Diabetes Care. 2010;33:1344-1346.
23. Har R, Scholey JW, Daneman D, Mahmud FH, Dekker R, Lai V, Elia Y, Fritzler ML, Sochett EB, Reich HN, Cherney DZ. The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Diabetologia. 2013;56:1166-1173.
24. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol. 1999;10:1778-1785.
25. Yang GK, Maahs DM, Perkins BA, Cherney DZ. Renal hyperfiltration and systemic blood pressure in patients with uncomplicated type 1 diabetes mellitus. PLoS One. 2013;8:e68908.
26. Metzger IF, Sertorio JT, Tanus-Santos JE. Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol (Oxf). 2006;188:123-127.
27. Cherney DZI, Scholey JW, Sochett EB. Gender differences in renal responses to hyperglycemia, l-arginine and l-nmma in humans with uncomplicated type 1 diabetes mellitus. Diabetes Care. 2012;Dec 18.
28. Shannon JA, Smith HW. The excretion of inulin, xylose and urea by normal and phlorizinized man. J Clin Invest. 1935;14:393-401.
29. Turkstra E, Braam B, Koomans HA. Nitric oxide release as an essential mitigating step in tubuloglomerular feedback: observations during intrarenal nitric oxide clamp. J Am Soc Nephrol. 1998;9:1596-1603.
30. Thorup C, Persson AE. Inhibition of locally produced nitric oxide resets tubuloglomerular feedback mechanism. Am J Physiol. 1994;267(4 Pt 2):F606-F611.
31. Ichihara A, Hayashi M, Koura Y, Tada Y, Sugaya T, Hirota N, Saruta T. Blunted tubuloglomerular feedback by absence of angiotensin type 1A receptor involves neuronal NOS. Hypertension. 2002;40:934-939.
32. Schnermann J, Levine DZ. Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol. 2003;65:501-529.
33. Thorup C, Ollerstam A, Persson AE, Torffvit O. Increased tubuloglomerular feedback reactivity is associated with increased NO production in the streptozotocin-diabetic rat. J Diabetes Complications. 2000;14:46-52.
34. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375-393.
35. L ist JF, Whaley JM. Glucose dynamics and mechanistic implications of sglt2 inhibitors in animals and humans. Kidney Int Suppl. 2011:S20-27.
36. Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res. 2012;9:117-123.
37. Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A, Scharf M, Tasic V, Greil J, Brinkert F, Kemper MJ, Santer R. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant. 2008;23:3874-3879.
38. Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Nephron. 1998;80:175-182.
39. Wing LM, Arnolda LF, Harvey PJ, Upton J, Molloy D, Gabb GM, Bune AJ, Chalmers JP. Low-dose diuretic and/or dietary sodium restriction when blood pressure is resistant to ACE inhibitor. Blood Press. 1998;7:299-307.
40. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356-362.
41. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463-473.
42. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin in patients with type 2 diabetes mellitus (t2d) and renal impairment. American Diabetes Association. 2013;Abstract 1104-P.
43. Mithal A, Barnett AH, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin in patients with type 2 diabetes mellitus (t2d) and stage 3a, 3b and 4 chronic kidney disease (ckd). European Society for the Study of Diabetes. 2013;Abstract.
44. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366-2376.
45. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40-51.
46. Magen D, Sprecher E, Zelikovic I, Skorecki K. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int. 2005;67:34-41.
47. Blantz RC, Pelayo JC. A functional role for the tubuloglomerular feedback mechanism. Kidney Int. 1984;25:739-746.
48. Kurkus J, Thorup C, Persson AE. Renal nerve stimulation restores tubuloglomerular feedback after acute renal denervation. Acta Physiol Scand. 1998;164:237-243.
49. Schreuder M, Delemarre-van de Waal H, van Wijk A. Consequences of intrauterine growth restriction for the kidney. Kidney Blood Press Res. 2006;29:108-125.
50. L umbers ER, Yu ZY, Gibson KJ. The selfish brain and the barker hypothesis. Clin Exp Pharmacol Physiol. 2001;28:942-947.